Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 1/2008

01.12.2008 | Original Article

Gemcitabine at fixed dose-rate in patients with advanced soft tissue sarcomas: a mono-institutional phase II study

verfasst von: Virginia Ferraresi, Mariangela Ciccarese, Maria Cecilia Cercato, Carmen Nuzzo, Massimo Zeuli, Franco Di Filippo, Diana Giannarelli, Francesco Cognetti

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To explore the clinical activity and toxicity of gemcitabine infused at the fixed dose of 10 mg/m2/min over 100 min in patients with soft tissue sarcomas (STSs).

Patients and methods

Fourteen patients with advanced locally unresectable and/or metastatic, pretreated STSs (seven leiomyosarcoma, three malignant schwannoma, one synovialsarcoma, one malignant fibrous histiocytoma, one endometrial stromal cell sarcoma, one undifferentiated) were treated with gemcitabine 10 mg/m2/min/week over 100 min given for 3 weeks out of 4. The median age was 52 years (range 27–77), male/female ratio was 3/11, and the median WHO performance status was 0 (range 0–1). The median number of previous medical treatments for advanced disease was 1 (range 1–2).

Results

A median number of three cycles (range 1–10 cycles) and a total of 151 weekly administrations (median 9, range 3–27) of gemcitabine were administered. Treatment was well tolerated and the main causes of dose-reduction or omission/delay were hematological and liver toxicities. One patient (7%; 95% confidence interval: 0.2–33.9%) with a metastatic uterine leiomyosarcoma obtained a partial response that lasted for 6.5 months. Three patients (two leiomyosarcoma and one schwannoma) (21%) obtained a stabilization of disease. The median time to progression was 3.1 months (range 1.0–9.5). The median overall survival was 11.8 months (range 1.0–54.5+).

Conclusions

Gemcitabine infused at the fixed dose of 10 mg/m2/min over 100 min shows a good tolerability but an overall modest activity in unselected STSs histotypes. Nevertheless, an interesting tumor growth control rate was observed in specific histological variants (i.e., leiomyosarcoma), thus confirming data from recent controlled clinical trials.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130PubMedCrossRef Jemal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130PubMedCrossRef
2.
Zurück zum Zitat Spira AI, Ettinger DS (2002) The use of chemotherapy in soft-tissue sarcomas. Oncologist 7:348–359PubMedCrossRef Spira AI, Ettinger DS (2002) The use of chemotherapy in soft-tissue sarcomas. Oncologist 7:348–359PubMedCrossRef
3.
Zurück zum Zitat Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V (1995) Gemcitabine: metabolism, mechanism of action, and self-potentiation. Semin Oncol 22:3–10PubMed Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V (1995) Gemcitabine: metabolism, mechanism of action, and self-potentiation. Semin Oncol 22:3–10PubMed
4.
Zurück zum Zitat Merimsky O, Meller I, Flusser G et al (2000) Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol 45:177–181PubMedCrossRef Merimsky O, Meller I, Flusser G et al (2000) Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol 45:177–181PubMedCrossRef
5.
Zurück zum Zitat Späth-Schwalbe E, Genvresse I, Koschuth A, Dietzmann A, Grunewald R, Possinger K (2000) Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs 11:325–329PubMedCrossRef Späth-Schwalbe E, Genvresse I, Koschuth A, Dietzmann A, Grunewald R, Possinger K (2000) Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs 11:325–329PubMedCrossRef
6.
Zurück zum Zitat Patel SR, Gandhi V, Jenkins J et al (2001) Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 19:3483–3489PubMed Patel SR, Gandhi V, Jenkins J et al (2001) Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 19:3483–3489PubMed
7.
Zurück zum Zitat Samuels BL, Barbour L, Schiller D (2001) Phase I study of low dose continuous infusion gemcitabine in sarcoma patients [abstract]. Proc Am Soc Clin Oncol 20:2935 Samuels BL, Barbour L, Schiller D (2001) Phase I study of low dose continuous infusion gemcitabine in sarcoma patients [abstract]. Proc Am Soc Clin Oncol 20:2935
8.
Zurück zum Zitat Bauer S, Hartung J, Gauler T et al (2002) Gemcitabine-containing chemotherapy in the treatment of patients with advanced soft tissue sarcoma. Tumordiagn Ther 23:219–224CrossRef Bauer S, Hartung J, Gauler T et al (2002) Gemcitabine-containing chemotherapy in the treatment of patients with advanced soft tissue sarcoma. Tumordiagn Ther 23:219–224CrossRef
9.
Zurück zum Zitat Look KY, Sandler A, Blessing JA, Lucci III JA, Rose PG (2004) Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. Gynecol Oncol 92:644–647PubMedCrossRef Look KY, Sandler A, Blessing JA, Lucci III JA, Rose PG (2004) Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. Gynecol Oncol 92:644–647PubMedCrossRef
10.
Zurück zum Zitat Abbruzzese JL, Grunewald R, Weeks EA et al (1991) A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491–498PubMed Abbruzzese JL, Grunewald R, Weeks EA et al (1991) A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491–498PubMed
11.
Zurück zum Zitat Pollera CF, Ceribelli A, Crecco M, Calabresi F (1994) Weekly gemcitabine in advanced or metastatic solid tumors. A clinical phase I study. Invest New Drugs 12:111–119PubMedCrossRef Pollera CF, Ceribelli A, Crecco M, Calabresi F (1994) Weekly gemcitabine in advanced or metastatic solid tumors. A clinical phase I study. Invest New Drugs 12:111–119PubMedCrossRef
12.
Zurück zum Zitat Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W (1990) Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res 50:6823–6826PubMed Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W (1990) Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res 50:6823–6826PubMed
14.
Zurück zum Zitat Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216PubMedCrossRef Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216PubMedCrossRef
15.
Zurück zum Zitat Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38:143–151PubMedCrossRef Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38:143–151PubMedCrossRef
16.
Zurück zum Zitat Touroutoglou N, Gravel D, Rabel MN, Plunkett W, Abbruzzese JL (1998) Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol 9:1003–1008PubMedCrossRef Touroutoglou N, Gravel D, Rabel MN, Plunkett W, Abbruzzese JL (1998) Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol 9:1003–1008PubMedCrossRef
17.
Zurück zum Zitat Brand R, Capadano M, Tempero M (1997) A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs 15:331–341PubMedCrossRef Brand R, Capadano M, Tempero M (1997) A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs 15:331–341PubMedCrossRef
18.
Zurück zum Zitat Amodio A, Carpano S, Manfredi C et al (1999) Gemcitabine in advanced soft tissue sarcoma: a phase II study. Clin Ter 150:17–20PubMed Amodio A, Carpano S, Manfredi C et al (1999) Gemcitabine in advanced soft tissue sarcoma: a phase II study. Clin Ter 150:17–20PubMed
19.
Zurück zum Zitat Gautam U, Hurley J, Silva OE, Benedetto PW, Robles C (2002) Gemcitabine: an active chemotherapeutic agent for angiosarcoma [abstract]. Proc Am Soc Clin Oncol 21:2931 Gautam U, Hurley J, Silva OE, Benedetto PW, Robles C (2002) Gemcitabine: an active chemotherapeutic agent for angiosarcoma [abstract]. Proc Am Soc Clin Oncol 21:2931
20.
Zurück zum Zitat Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S, Galanis E (2002) Phase II trial of gemcitabine in advanced sarcomas. Cancer 94:3225–3229PubMedCrossRef Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S, Galanis E (2002) Phase II trial of gemcitabine in advanced sarcomas. Cancer 94:3225–3229PubMedCrossRef
21.
Zurück zum Zitat Švancárová L, Blay JY, Judson IR et al (2002) Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38:556–559PubMedCrossRef Švancárová L, Blay JY, Judson IR et al (2002) Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38:556–559PubMedCrossRef
22.
Zurück zum Zitat Okuno S, Ryan LM, Edmonson JH, Priebat DA, Blum RH (2003) Phase II trial of gemcitabine in patients with advanced sarcomas (E1797). A trial of the Eastern Cooperative Oncology Group. Cancer 97:1969–1973PubMedCrossRef Okuno S, Ryan LM, Edmonson JH, Priebat DA, Blum RH (2003) Phase II trial of gemcitabine in patients with advanced sarcomas (E1797). A trial of the Eastern Cooperative Oncology Group. Cancer 97:1969–1973PubMedCrossRef
23.
Zurück zum Zitat Hartmann JT, Oechsle K, Huober J et al (2006) An open label, non comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Invest New Drugs 24:249–253PubMedCrossRef Hartmann JT, Oechsle K, Huober J et al (2006) An open label, non comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Invest New Drugs 24:249–253PubMedCrossRef
24.
Zurück zum Zitat Von Burton G, Rankin C, Zalupski MM, Mills GM, Borden EC, Karen A (2006) Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma. Am J Clin Oncol 29:59–61CrossRef Von Burton G, Rankin C, Zalupski MM, Mills GM, Borden EC, Karen A (2006) Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma. Am J Clin Oncol 29:59–61CrossRef
25.
Zurück zum Zitat Hensley ML, Maki R, Venkatraman E et al (2002) Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20:2824–2831PubMedCrossRef Hensley ML, Maki R, Venkatraman E et al (2002) Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20:2824–2831PubMedCrossRef
26.
Zurück zum Zitat Maki RG, Wathen JK, Patel SR et al (2007) Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of Sarcoma Alliance for Research through collaboration study 002 (corrected). J Clin Oncol 25:2755–2763PubMedCrossRef Maki RG, Wathen JK, Patel SR et al (2007) Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of Sarcoma Alliance for Research through collaboration study 002 (corrected). J Clin Oncol 25:2755–2763PubMedCrossRef
27.
Zurück zum Zitat Buesa JM, Losa R, Fernández A et al (2004) Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation. Cancer 101:2261–2269PubMedCrossRef Buesa JM, Losa R, Fernández A et al (2004) Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation. Cancer 101:2261–2269PubMedCrossRef
28.
Zurück zum Zitat Losa R, Fra J, López-Pousa A et al (2007) Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. Cancer Chemother Pharmacol 59:251–259PubMedCrossRef Losa R, Fra J, López-Pousa A et al (2007) Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. Cancer Chemother Pharmacol 59:251–259PubMedCrossRef
29.
Zurück zum Zitat López-Pousa A, Losa R, Martin J et al (2006) Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study. Br J Cancer 94:1797–1802PubMedCrossRef López-Pousa A, Losa R, Martin J et al (2006) Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study. Br J Cancer 94:1797–1802PubMedCrossRef
30.
Zurück zum Zitat Dileo P, Morgan JA, Zahrieh D et al (2007) Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer 109:1863–1869PubMedCrossRef Dileo P, Morgan JA, Zahrieh D et al (2007) Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer 109:1863–1869PubMedCrossRef
31.
Zurück zum Zitat Xu N, Shen P, Zhang XC et al (2007) Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 59:1–7PubMedCrossRef Xu N, Shen P, Zhang XC et al (2007) Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 59:1–7PubMedCrossRef
32.
Zurück zum Zitat Pereira JR, Fein L, Del Giglio A et al (2007) Gemcitabine administered as a short infusion versus a fixed dose rate in combination with cisplatin for the treatment of patients with advanced non-small cell lung cancer. Lung Cancer 58:80–87PubMedCrossRef Pereira JR, Fein L, Del Giglio A et al (2007) Gemcitabine administered as a short infusion versus a fixed dose rate in combination with cisplatin for the treatment of patients with advanced non-small cell lung cancer. Lung Cancer 58:80–87PubMedCrossRef
33.
Zurück zum Zitat Kim H, Park JH, Shin SJ et al (2008) Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: a phase II study. Chemotherapy 54:54–62PubMedCrossRef Kim H, Park JH, Shin SJ et al (2008) Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: a phase II study. Chemotherapy 54:54–62PubMedCrossRef
34.
Zurück zum Zitat Sun W, Hewitt MR, Theobald MR, Hershock D, Haller DG (2007) A phase I study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer. Cancer 110:2768–2774PubMedCrossRef Sun W, Hewitt MR, Theobald MR, Hershock D, Haller DG (2007) A phase I study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer. Cancer 110:2768–2774PubMedCrossRef
35.
Zurück zum Zitat Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ; Cancer, Leukemia Group B (2008) A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. BJU Int 101:20–25 Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ; Cancer, Leukemia Group B (2008) A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. BJU Int 101:20–25
Metadaten
Titel
Gemcitabine at fixed dose-rate in patients with advanced soft tissue sarcomas: a mono-institutional phase II study
verfasst von
Virginia Ferraresi
Mariangela Ciccarese
Maria Cecilia Cercato
Carmen Nuzzo
Massimo Zeuli
Franco Di Filippo
Diana Giannarelli
Francesco Cognetti
Publikationsdatum
01.12.2008
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 1/2008
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-008-0723-9

Weitere Artikel der Ausgabe 1/2008

Cancer Chemotherapy and Pharmacology 1/2008 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.